- Home
- LTBR vs SLN Comparison
LTBR vs SLN Comparison
Compare LTBR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTBR
- SLN
- Stock Information
- Founded
- LTBR 1992
- SLN 1994
- Country
- LTBR United States
- SLN United Kingdom
- Employees
- LTBR N/A
- SLN N/A
- Industry
- LTBR Professional Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- LTBR Consumer Discretionary
- SLN Health Care
- Exchange
- LTBR Nasdaq
- SLN Nasdaq
- Market Cap
- LTBR 397.8M
- SLN 299.4M
- IPO Year
- LTBR N/A
- SLN N/A
- Fundamental
- Price
- LTBR $15.13
- SLN $4.81
- Analyst Decision
- LTBR
- SLN Buy
- Analyst Count
- LTBR 0
- SLN 5
- Target Price
- LTBR N/A
- SLN $32.60
- AVG Volume (30 Days)
- LTBR 1.5M
- SLN 61.8K
- Earning Date
- LTBR 08-11-2025
- SLN 08-07-2025
- Dividend Yield
- LTBR N/A
- SLN N/A
- EPS Growth
- LTBR N/A
- SLN N/A
- EPS
- LTBR N/A
- SLN N/A
- Revenue
- LTBR N/A
- SLN $27,169,000.00
- Revenue This Year
- LTBR N/A
- SLN N/A
- Revenue Next Year
- LTBR N/A
- SLN N/A
- P/E Ratio
- LTBR N/A
- SLN N/A
- Revenue Growth
- LTBR N/A
- SLN 22.28
- 52 Week Low
- LTBR $2.24
- SLN $1.97
- 52 Week High
- LTBR $18.80
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- LTBR 52.17
- SLN 34.88
- Support Level
- LTBR $12.93
- SLN $4.91
- Resistance Level
- LTBR $16.19
- SLN $5.34
- Average True Range (ATR)
- LTBR 1.48
- SLN 0.48
- MACD
- LTBR -0.02
- SLN -0.05
- Stochastic Oscillator
- LTBR 37.48
- SLN 0.71
About LTBR Lightbridge Corporation
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.